Please login to the form below

Not currently logged in
Email:
Password:

GSK trials shingles vaccine

GlaxoSmithKline has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles

GlaxoSmithKline (GSK) has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles.

The phase III clinical programme will study more than 30,000 patients worldwide and will evaluate the efficacy, safety and immunogenicity of the vaccine.

Norman Begg, chief medical officer of GSK Biologicals said: "The commencement of the phase III programme for our candidate's herpes zoster vaccine is a significant milestone. Shingles is an often debilitating condition for which there are limited treatment and prevention options.

"Progression into late-stage development of our herpes zoster vaccine is an important milestone in ongoing efforts to potentially help address an important unmet need," he added.

Herpes zoster is commonly known as shingles. It is caused by the varicella-zoster virus (VZV) and occurs in around 3 out of 1,000 people per year in Europe.

24th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Innovation and agility
Start small but think big
Exploring the potential of agility in unlocking creativity...
The Pivot
In times of uncertainty it is critical for businesses to take action to protect their brand image and longevity....
Peter Jackson
The global antibiotic crisis: a 2020 perspective
A report from the CDC says the ‘approaching’ post-antibiotic era is already here...

Infographics